Literature DB >> 10960842

Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes.

M T del Vecchio1, S A Tripodi, F Arcuri, L Pergola, L Hako, R Vatti, M Cintorino.   

Abstract

BACKGROUND: Macrophage migration inhibitory factor (MIF) is a ubiquitary cytokine whose expression has been investigated in tumors, showing a correlation between tumor aggressiveness and production of this protein by neoplastic cells. The aim of our study was to correlate MIF expression with tumor grade (Gleason scoring system) and histopathological changes after combined endocrine treatment (CET) of prostate adenocarcinoma.
METHODS: We analyzed MIF immunoreactivity in 124 paired needle biopsies and radical prostatectomy specimens from 62 prostate cancer patients, of which 20 had been treated with CET.
RESULTS: In untreated prostates, MIF expression significantly correlated with tumor grading, being stronger in low-grade than in high-grade adenocarcinoma. In treated prostates, histopathological changes also correlated with MIF immunoreactivity, but not in a significant manner.
CONCLUSIONS: The results of the current study demonstrated that with histological dedifferentiation, prostate adenocarcinoma cells show a reduced MIF expression. This finding may be the consequence of a reduced MIF synthesis or the result of an enhanced and altered secretion by tumor cells into the surrounding stroma. The consequent abnormal interaction between MIF and environmental factors might influence tumor growth and diffusion. On the other hand, the minor but not significantly reduced MIF expression by tumor cells after CET seems to exclude a hormonal regulation of MIF secretion. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960842     DOI: 10.1002/1097-0045(20000915)45:1<51::aid-pros6>3.0.co;2-9

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  28 in total

1.  Clinicopathological significance of macrophage migration inhibitory factor and its relation with p53 in gastric cancer.

Authors:  Majid Nabizadeh Marvast; Hamid Reza Sima; Kamran Ghaffarzadehgan; Ali Taghizadeh Kermani; Nona Norouzi
Journal:  J Gastrointest Cancer       Date:  2011-03

Review 2.  Janus-faces of NME-oncoprotein interactions.

Authors:  Nikolina Vlatković; Shie-Hong Chang; Mark T Boyd
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-01       Impact factor: 3.000

3.  Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas.

Authors:  Chia-Tung Shun; Jaw-Town Lin; Shih-Pei Huang; Min-Tsan Lin; Ming-Shiang Wu
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

4.  Molecular alterations in primary prostate cancer after androgen ablation therapy.

Authors:  Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

5.  Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses.

Authors:  Olivia Twu; Daniele Dessí; Anh Vu; Frances Mercer; Grant C Stevens; Natalia de Miguel; Paola Rappelli; Anna Rita Cocco; Robert T Clubb; Pier Luigi Fiori; Patricia J Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

6.  Association Between Genetic Polymorphism of the MIF Gene and Colorectal Cancer in Taiwan.

Authors:  Latha Ramireddy; William Tzu-Liang Chen; Ching-Tien Peng; Rouh-Mei Hu; Tao-Wei Ke; Hua-Che Chiang; Sheng-Chi Chang; Fuu-Jen Tsai; Wan-Yu Lo
Journal:  J Clin Lab Anal       Date:  2014-05-19       Impact factor: 2.352

Review 7.  The emerging roles of Jab1/CSN5 in cancer.

Authors:  Lin Wang; Jun-Nian Zheng; Dong-Sheng Pei
Journal:  Med Oncol       Date:  2016-07-13       Impact factor: 3.064

8.  Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor.

Authors:  Mei-Yi Wu; Junjiang Fu; Jianming Xu; Bert W O'Malley; Ray-Chang Wu
Journal:  Cell Res       Date:  2012-03-20       Impact factor: 25.617

Review 9.  Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation.

Authors:  Beatriz E Rendon; Sharon S Willer; Wayne Zundel; Robert A Mitchell
Journal:  Exp Mol Pathol       Date:  2009-01-07       Impact factor: 3.362

10.  The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer.

Authors:  Hakan Camlica; Derya Duranyildiz; Hilal Oguz; Ethem Nezih Oral; Vildan Yasasever
Journal:  Pathol Oncol Res       Date:  2008-03-18       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.